| Literature DB >> 26046700 |
Ellen L Danneels1, Ellen M Formesyn2, Dirk C de Graaf3.
Abstract
The venom from the ectoparasitoid wasp Nasonia vitripennis (Hymenoptera: Pteromalidae) contains at least 80 different proteins and possibly even more peptides or other small chemical compounds, demonstrating its appealing therapeutic application. To better understand the dynamics of the venom in mammalian cells, two high-throughput screening tools were performed. The venom induced pathways related to an early stress response and activated reporters that suggest the involvement of steroids. Whether these steroids reside from the venom itself or show an induced release/production caused by the venom, still remains unsolved. The proinflammatory cytokine IL-1β was found to be down-regulated after venom and LPS co-treatment, confirming the anti-inflammatory action of N. vitripennis venom. When analyzing the expression levels of the NF-κB target genes, potentially not only the canonical but also the alternative NF-κB pathway can be affected, possibly explaining some counterintuitive results. It is proposed that next to an NF-κB binding site, the promoter of the genes tested by the PCR array may also contain binding sites for other transcription factors, resulting in a complex puzzle to connect the induced target gene with its respective transcription factor. Interestingly, Nasonia venom altered the expression of some drug targets, presenting the venom with an exciting therapeutical potential.Entities:
Keywords: NF-κB; Nasonia; PCR array; reporter array; therapeutic; venom
Mesh:
Substances:
Year: 2015 PMID: 26046700 PMCID: PMC4488689 DOI: 10.3390/toxins7062051
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Effect of N. vitripennis venom in HEK293T cells, either induced with TNFα or not, on the transcriptional activity of reporters of 45 different pathways. Fold regulation (FR) of all tested reporters are presented for 3 different comparisons. When p > 0.05, insignificant values are between brackets; when |FR| > 2, values are in bold.
| Pathway reporters | FR TNFα-treated | FR Venom-treated | FR TNFα- and venom-treated |
|---|---|---|---|
| AARE reporter | 1.601 | ||
| AR reporter | (1.291) | ||
| C/EBP reporter | (1.274) | 1.925 | |
| CRE reporter | 1.779 | (1.457) | |
| E2F reporter | 1.001 | (1.012) | |
| p53 reporter | ( | ( | |
| EGR1 reporter | (−0.911) | (1.548) | |
| HSR reporter | (−0.901) | (1.311) | |
| GLI reporter | (−0.240) | ||
| IRF1 reporter | −1.188 | (1.287) | |
| LXR reporter | (−0.342) | 1.622 | |
| MEF2 reporter | −1.192 | ||
| NF-κB reporter | (−1.272) | (1.145) | |
| Oct4 reporter | (−1.436) | ||
| PR reporter | (−0.126) | (1.718) | |
| RARE reporter | (−0.702) | (−0.048) | |
| RXR reporter | (−0.370) | (1.379) |
Effect of N. vitripennis venom in Raw264.7 cells, either induced with lipopolysaccharide (LPS) or not, on NF-κB signaling targets. Fold regulation of all tested NF-κB signaling target genes are presented for 3 different comparisons. When p > 0.05, insignificant values are between brackets; when |FR| > 2, values are in bold. (Abb = abbreviation; FR = fold regulation).
| NF-κB signaling target genes | Abb | FR LPS-treated | FR venom-treated | FR LPS- and venom-treated | ||||
|---|---|---|---|---|---|---|---|---|
| Chemokine (C–C motif) ligand 22 | Ccl22 | (1.032) | (−1.532) | |||||
| Chemokine (C–C motif) ligand 5 | Ccl5 | (2.107) | (1.750) | |||||
| Chemokine (C–C motif) receptor 5 | Ccr5 | 1.625 | (1.875) | (2.346) | ||||
| Chemokine (C–X–C motif) ligand 10 | Cxcl10 | (2.254) | (−1.025) | |||||
| Chemokine (C–X–C motif) ligand 3 | Cxcl3 | (3.484) | (34.595) | |||||
| Interleukin 15 | Il15 | (3.325) | (2.527) | |||||
| Interleukin 1α | Il1a | (2.414) | (−1.242) | |||||
| Interleukin 1β | Il1b | |||||||
| Interleukin 1 receptor antagonist | Il1rn | (3.074) | (−1.145) | |||||
| Interleukin 6 | Il6 | (2.419) | −1.472 | |||||
| Lymphotoxin A | Lta | (3.037) | (1.094) | |||||
| Tumor necrosis factor | Tnf | (−1.244) | −1.193 | |||||
| CD40 antigen | Cd40 | (4.098) | ||||||
| CD80 antigen | Cd80 | (2.621) | (2.723) | |||||
| CD83 antigen | Cd83 | (3.545) | (2.949) | |||||
| Tumor necrosis factor receptor superfamily, member 1b | Tnfrsf1b | (1.469) | (1.708) | |||||
| Complement component 3 | C3 | (2.035) | (1.175) | |||||
| Complement factor B | Cfb | −(1.007) | ||||||
| Intercellular adhesion molecule 1 | Icam1 | (1.405) | (1.212) | |||||
| Vascular cell adhesion molecule 1 | Vcam1 | (−1.148) | (1.387) | |||||
| Coagulation factor III | F3 | (4.466) | (−1.979) | |||||
| NAD(P)H dehydrogenase, quinone 1 | Nqo1 | (−1.247) | (3.014) | |||||
| Prostaglandin-endoperoxide synthase 2 | Ptgs2 | (1.715) | (−1.605) | |||||
| Superoxide dismutase 2, mitochondrial | Sod2 | −1.052 | (1.301) | |||||
| B-cell leukemia/lymphoma 2 related protein A1a | Bcl2a1a | (3.713) | ||||||
| Bcl2-like 1 | Bcl2l1 | (1.255) | (1.275) | |||||
| Baculoviral IAP repeat-containing 2 | Birc2 | (−1.428) | (1.513) | |||||
| Baculoviral IAP repeat-containing 3 | Birc3 | 1.874 | (1.558) | |||||
| Fas (TNF receptor superfamily member 6) | Fas | |||||||
| Tnf receptor-associated factor 2 | Traf2 | (−1.056) | 1.983 | |||||
| Colony stimulating factor 1 (macrophage) | Csf1 | |||||||
| Colony stimulating factor 2 (granulocyte-macrophage) | Csf2 | (1.548) | (−1.436) | |||||
| Colony stimulating factor 3 (granulocyte) | Csf3 | |||||||
| Platelet derived growth factor, B polypeptide | Pdgfb | (1.479) | (1.092) | |||||
| Interferon regulatory factor 1 | Irf1 | (2.039) | ||||||
| Microphthalmia-associated transcription factor | Mitf | (−1.549) | (1.434) | |||||
| Myelocytomatosis oncogene | Myc | (8.083) | ||||||
| Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, p105 | Nfkb1 | (1.599) | ||||||
| Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, p49/p100 | Nfkb2 | (1.368) | (1.001) | |||||
| Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha | Nfkbia | (1.102) | (1.508) | |||||
| Reticuloendotheliosis oncogene | Rel | (1.121) | ||||||
| Avian reticuloendotheliosis viral (v-rel) oncogene related B | Relb | (1.334) | ||||||
| Signal transducer and activator of transcription 1 | Stat1 | −1.257 | (1.111) | |||||
| Signal transducer and activator of transcription 3 | Stat3 | 1.517 | −1.104 | −1.444 | ||||
| Cyclin D1 | Ccnd1 | |||||||
| Growth arrest and DNA-damage-inducible 45 beta | Gadd45b | (2.325) | ||||||
| Matrix metallopeptidase 9 | Mmp9 | (1.635) | ||||||
TF binding sites that are commonly present in the promoters of 5 up-regulated genes tested by the NF-κB Signaling Targets PCR Array, predicted by TFSEARCH (threshold 85.0). The presence of these TF binding sites is shown for 4 down-regulated genes when cells were treated with venom and LPS. “x” represents the presence of the respective TF site in the promoter region of that particular gene. At the bottom, the fold regulations are presented for the selected genes.
| NF-κB signaling target genes | Cd83 | Csf1 | IL15 | Irf1 | Icam1 | Il1b | Csf3 | Mmp9 | Ccnd1 |
|---|---|---|---|---|---|---|---|---|---|
| NF-Kap | x | x | x | x | x | x | x | x | x |
| C/EBP | x | x | x | x | x | x | x | x | - |
| C/EBPa | x | x | x | - | x | - | x | x | - |
| AML-1a | x | x | x | x | x | x | x | x | x |
| CdxA | x | x | x | x | x | x | x | x | x |
| CRE-BP | x | x | x | x | x | x | - | - | - |
| deltaE | x | x | x | x | x | x | x | x | x |
| GATA-1 | x | x | x | x | x | x | x | x | x |
| GATA-2 | x | x | x | x | x | x | x | x | x |
| GATA-3 | x | x | x | x | x | - | x | x | x |
| GATA-X | x | x | x | x | x | x | x | - | x |
| HSF2 | x | x | x | x | x | x | - | x | - |
| MZF1 | x | x | x | x | x | x | x | x | x |
| Nkx-2. | x | x | x | x | x | x | x | x | x |
| Oct-1 | x | x | x | x | x | x | x | x | - |
| SRY | x | x | x | x | x | x | x | x | x |
| TATA | x | x | x | x | x | x | - | x | x |
| venom- and LPS- | 29.4 | 117.8 | 13.4 | 14.0 | 17.6 | −4.4 | −31.7 | −5.8 | −7.4 |
| venom-treated | 3.0 | 55.9 | 2.5 | 2.0 | 1.2 | 5.9 | 5.5 | 1.6 | −2.7 |
NF-κB target genes that were differentially transcribed and can be a possible drug target of N. vitripennis venom. Three different comparisons are presented: venom-treated versus untreated, venom- and LPS-treated versus LPS-treated cells and LPS-treated versus untreated. When p > 0.05, insignificant values are between brackets; when |FR| >2, values are in bold. (Abb = abbreviation; FR = fold regulation; Ref = reference).
| Possible drug targets of venom | Abb | FR venom | FR venom- and LPS- treated | FR LPS-treated | Potential targeted diseases | Reference |
|---|---|---|---|---|---|---|
| NAD(P)H dehydrogenase, quinone 1 | Nqo1 | ( | (−1.247) | acute leukemia | [ | |
| Cyclin D1 | Ccnd1 | breast cancer | [ | |||
| Interferon regulatory factor 1 | Irf1 | ( | breast cancer | [ | ||
| Matrix metallopeptidase 9 | Mmp9 | (1.635) | cancer | [ | ||
| Colony stimulating factor 3 (granulocyte) | Csf3 | inflammatory arthritis | [ | |||
| Interleukin 1 beta | Il1b | autoinflammatory diseases | [ | |||
| Complement factor B | Cfb | (−1.007) | complement mediated inflammatory diseases | [ |